Diffuse Large B Cell Lymphoma Clinical Trials

816 clinical trials for Diffuse Large B Cell Lymphoma across international registries, including 189 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) — RECRUITING · PHASE3
• A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) — RECRUITING · PHASE2
• Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma — RECRUITING · PHASE2
• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma — RECRUITING · PHASE1
• Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies — RECRUITING · PHASE1
• Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies — RECRUITING · PHASE1
• A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma — RECRUITING · PHASE3
• LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies — RECRUITING · PHASE1
• A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies — RECRUITING · PHASE1
• An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma — RECRUITING
• Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL — RECRUITING · PHASE2
• Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) — RECRUITING
• Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) — RECRUITING · PHASE1
• A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy — RECRUITING · PHASE3
• A Long-term Extension Study of PCI-32765 (Ibrutinib) — RECRUITING · PHASE3
• A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies — RECRUITING · PHASE1
• IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas — RECRUITING · PHASE1
• CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL — RECRUITING · PHASE2
• The CARDIOPROTECT Trial — RECRUITING · PHASE2
• Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) — RECRUITING · PHASE1
• Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing — RECRUITING
• A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma — RECRUITING · PHASE2
• Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL — RECRUITING · PHASE2
• Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype — RECRUITING · PHASE2
• A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas — RECRUITING · PHASE1
• A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2) — RECRUITING · PHASE3
• Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms — RECRUITING
• Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma — RECRUITING · PHASE1
• Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma — RECRUITING
• A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies — RECRUITING · PHASE1
• Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies — RECRUITING · PHASE1
• A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma — RECRUITING · PHASE3
• A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma — RECRUITING
• Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients — RECRUITING · PHASE1
• Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas — RECRUITING · PHASE1
• Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma — RECRUITING · PHASE3
• Study of Out of Specification for Tisagenlecleucel — RECRUITING · PHASE3
• Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL) — RECRUITING · PHASE1
• Hyperfractionated Dual Equivalent Fractionated Radiation Therapy — RECRUITING · NA
• Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma? — RECRUITING · NA
• Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission — RECRUITING · PHASE2
• Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients — RECRUITING · PHASE2
• R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma — RECRUITING · PHASE1
• Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution — RECRUITING
• External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL — RECRUITING · PHASE1
• Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes — RECRUITING · PHASE2
• Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression — RECRUITING · PHASE2
• Prospective Examination on Neurocognitive Outcomes Following Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy — RECRUITING
• The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk — RECRUITING · PHASE3

Refine this search